glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results Get With the FLOW! in: News Volume 16 Issue 8 (2024) Semaglutide could be 'practice changing'
Description
This increase is believed to be largely attributed to resolving GLP-1 drug shortages in 2024
Glucagon-like peptide 2
Overall, semaglutide was associated with improved glycaemic control, when used either as monotherapy or as add-on therapy in patients with T2DM against both placebo and active comparators (including other GLP-1 RAs)
GLP-1 is released primarily from the ileum and colon in the response to food intake
The slowed gastric emptying and reduced food intake both contribute
Therefore, patients with unpredictable schedules may struggle with consistent absorption when using a GLP-1 pill regimen
